EGFR and head and neck squamous cell carcinoma: The overexpression of Epidermal Growth Factor Receptor (EGFR) in >90% of head and neck squamous cell carcinoma (HNSCC) lesions correlates with adverse prognosis [1,2,3,4], and was used as a rationale to evaluate the effect of EGFR-targeted therapies [5].